Christine L. Latham

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · Clinical Infectious Diseases · 2023 · 124 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Chloe Orkin, Jonathan Schapiro, Carlo Federico Perno et al. · Clinical Infectious Diseases · 2023 · 124 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Moti Ramgopal, Antonella Castagna, Charles Cazanave et al. · The Lancet HIV · 2023 · 115 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Nurses Supporting Nurses

Christine L. Latham, Mikel Hogan, Karen Ringl · Nursing Administration Quarterly · 2008 · 88 citations

Nursing, Advanced Practice Nursing, Nursing Administration +14

Call to action: Blueprint for change in acute and critical care nursing

Martha A. Q. Curley, Margarete L. Zalon, Maureen A. Seckel et al. · Nursing Outlook · 2024 · 42 citations · Full text

Nursing, Advanced Practice Nursing, Critical Care Nursing +12